441 related articles for article (PubMed ID: 27807948)
1. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
[TBL] [Abstract][Full Text] [Related]
3. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
[TBL] [Abstract][Full Text] [Related]
4. Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation.
de la Torre Hernández JM; Tejedor P; Camarero TG; Duran JM; Lee DH; Monedero J; Laso FS; Calderón MA; Veiga G; Zueco J
Catheter Cardiovasc Interv; 2016 Sep; 88(3):E67-73. PubMed ID: 26526783
[TBL] [Abstract][Full Text] [Related]
5. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
6. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
[TBL] [Abstract][Full Text] [Related]
7. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
8. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial.
Gomez-Lara J; Brugaletta S; Ortega-Paz L; Vandeloo B; Moscarella E; Salas M; Romaguera R; Roura G; Ferreiro JL; Teruel L; Gracida M; Windecker S; Serruys PW; Gomez-Hospital JA; Sabaté M; Cequier A
JACC Cardiovasc Interv; 2018 Aug; 11(16):1559-1571. PubMed ID: 29805111
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
[TBL] [Abstract][Full Text] [Related]
11. An observational study of clinical outcomes of everolimus-eluting bioresorbable scaffolds comparing the procedural use of optical coherence tomography against angiography alone.
Hamshere S; Byrne A; Guttmann O; Rees P; Bourantas C; Weerakody R; Wragg A; Knight C; Mathur A; Jones DA
Coron Artery Dis; 2018 Sep; 29(6):482-488. PubMed ID: 29642228
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
Kereiakes DJ; Windecker S; Jobe RL; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Underwood P; Allocco DJ; Meredith IT
Circ Cardiovasc Interv; 2019 Sep; 12(9):e008152. PubMed ID: 31451014
[TBL] [Abstract][Full Text] [Related]
13. Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies.
Tarantini G; Masiero G; Barioli A; Paradies V; Vlachojannis G; Tellaroli P; Cortese B; di Palma G; Varricchio A; Ielasi A; Loi B; Steffenino G; Ueshima D; Mojoli M; Smits P
Catheter Cardiovasc Interv; 2018 Aug; 92(2):E115-E124. PubMed ID: 29513403
[TBL] [Abstract][Full Text] [Related]
14. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
[TBL] [Abstract][Full Text] [Related]
16. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
17. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
[TBL] [Abstract][Full Text] [Related]
18. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
19. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
[TBL] [Abstract][Full Text] [Related]
20. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.
Costopoulos C; Latib A; Naganuma T; Sticchi A; Ferrarello S; Regazzoli D; Chieffo A; Figini F; Carlino M; Montorfano M; Naim C; Kawaguchi M; Gerasimou A; Giannini F; Godino C; Colombo A
Catheter Cardiovasc Interv; 2014 May; 83(6):889-95. PubMed ID: 23804318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]